Lastly, mutations in ERK were found to confer resistance to ERK and Raf/MEK inhibitors by disrupting drug binding and maintaining levels of ERK activity in B-raf mutant melanoma cells (Goetz et al., 2014). Here, MAPK1 is linked to melanoma.